OncRef

Clinical Trial: NCT02601313

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Kite, A Gilead Company
Information Provided By:Gilead Sciences
Last Update Posted:2026-03-18

Study Overview

Brief Summary

The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).

Official Title

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma

Conditions

Relapsed/Refractory Mantle Cell Lymphoma

Intervention / Treatment

  • Biological: brexucabtagene autoleucel
  • Drug: Cyclophosphamide
  • Drug: Fludarabine
  • Drug: Axicabtagene Ciloleucel

Other Study ID Numbers

  • KTE-C19-102
  • 2015-005008-27
  • 2023-506641-35
  • 2023
  • 2015

Start Date (Actual)

2015-11-09

Primary Completion Date (Actual)

2023-09-22

Study Completion Date (Actual)

2023-09-22

Enrollment (Actual)

105

Study Type

Interventional

Phase

Phase 2